Since Amjevita is a biosimilar of Humira, they share some of the same side effects. For example, injection site reactions, such as swelling and itching, are a common side effect seen with both drugs.

Both infliximab and adalimumab are safe and effective in achieving remission in patients with severe mucocutaneous Behçet syndrome, with adalimumab demonstrating a quicker response time; both ...

Pariser DM, Lebwohl MG, Jaworski J, et al. CT-P17 adalimumab biosimilar in patients with moderate-to-severe chronic plaque psoriasis: An open-label extension of a phase 3 interchangeability study.

Medically reviewed by Mary Choy, PharmD Biologics work by targeting proteins that cause inflammation in ulcerative colitis. As a result, certain biologics help decrease flare-ups and complications.

A total of 231 participants receiving adalimumab with methotrexate and 1553 receiving adalimumab monotherapy were included in the cohort. 1 At 1 year, drug survival was 79.1% (95% CI, 71.8% to 87. ...

Upadacitinib demonstrated greater clinical efficacy and a comparable safety profile to adalimumab for treating RA, regardless of patients’ baseline CV risks.

The cohort included 11,400 adults who had psoriasis (60.7% men, mean age 45.3 years). The new user analysis included those with moderate to severe psoriasis with no history of adalimumab, 5,416 ...

Unlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.

HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial ...